# Nano Dimension Ltd.: financial statements, quarterly

NNDM · Nasdaq · CIK 1643303 · [Technology](/sectors/technology.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/nndm.md) · [Financials](/companies/nndm/financials.md) · [Filings](/companies/nndm/filings.md) · [Insiders](/companies/nndm/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/nndm/financials.md?period=annual).

## Income statement

| Line item | Unit | period not labelled (2025-03-31) | period not labelled (2025-06-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: |
| Revenue | $m | [14.4](/filings/0001193125-26-211930.md) | [25.8](/filings/0001193125-26-338523.md) | [29.7](/filings/0001193125-26-211930.md) | [29.0](/filings/0001193125-26-338523.md) |
| Cost of revenue | $m | [8.6](/filings/0001193125-26-211930.md) | [18.8](/filings/0001193125-26-338523.md) | [17.6](/filings/0001193125-26-211930.md) | [15.7](/filings/0001193125-26-338523.md) |
| Gross profit | $m | [5.8](/filings/0001193125-26-211930.md) | [7.0](/filings/0001193125-26-338523.md) | [12.1](/filings/0001193125-26-211930.md) | [13.3](/filings/0001193125-26-338523.md) |
| Research and development | $m | [5.9](/filings/0001193125-26-211930.md) | [8.1](/filings/0001193125-26-338523.md) | [8.2](/filings/0001193125-26-211930.md) | [5.8](/filings/0001193125-26-338523.md) |
| Operating income | $m | [(41.9)](/filings/0001193125-26-211930.md) | [(41.6)](/filings/0001193125-26-338523.md) | [(64.5)](/filings/0001193125-26-211930.md) | [(20.6)](/filings/0001193125-26-338523.md) |
| Interest expense | $m | [1.7](/filings/0001193125-26-211930.md) | [0.2](/filings/0001193125-26-338523.md) | [0.2](/filings/0001193125-26-211930.md) | [0.2](/filings/0001193125-26-338523.md) |
| Income tax | $m | [0.0](/filings/0001193125-26-211930.md) | [0.1](/filings/0001193125-26-338523.md) | [0.0](/filings/0001193125-26-211930.md) | [0.2](/filings/0001193125-26-338523.md) |
| Net income | $m | [(25.3)](/filings/0001193125-26-211930.md) | [(181)](/filings/0001193125-26-338523.md) | [(69.7)](/filings/0001193125-26-211930.md) | [(6.8)](/filings/0001193125-26-338523.md) |
| Diluted EPS | $ per share | [(0.12)](/filings/0001193125-26-211930.md) | [(0.83)](/filings/0001193125-26-338523.md) | [(0.34)](/filings/0001193125-26-211930.md) | [(0.03)](/filings/0001193125-26-338523.md) |
| Basic EPS | $ per share | [(0.12)](/filings/0001193125-26-211930.md) | [(0.83)](/filings/0001193125-26-338523.md) | [(0.34)](/filings/0001193125-26-211930.md) | [(0.03)](/filings/0001193125-26-338523.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfRevenue
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpenseNonoperating
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | FY2018 (2018-12-31) | FY2019 (2019-12-31) | FY2020 (2020-12-31) | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | period not labelled (2025-03-31) | period not labelled (2025-06-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [3.8](/filings/0001213900-22-016405.md) | [3.9](/filings/0001213900-22-016405.md) | [585](/filings/0001213900-24-024783.md) | [854](/filings/0001410578-25-001194.md) | [685](/filings/0001410578-25-001194.md) | [310](/filings/0001193125-26-134641.md) | [317](/filings/0001193125-26-134641.md) | [487](/filings/0001193125-26-211930.md) | [185](/filings/0001193125-26-338523.md) | [205](/filings/0001193125-26-134641.md) | [355](/filings/0001193125-26-211930.md) | [349](/filings/0001193125-26-338523.md) |
| Current assets | $m | [8.8](/filings/0001213900-20-005813.md) | [9.9](/filings/0001213900-21-014712.md) | [676](/filings/0001213900-22-016405.md) | [1,312](/filings/0001213900-23-024297.md) | [1,064](/filings/0001213900-24-024783.md) | [894](/filings/0001410578-25-001194.md) | [789](/filings/0001193125-26-134641.md) | not reported | not reported | [526](/filings/0001193125-26-338523.md) | [505](/filings/0001193125-26-211930.md) | [497](/filings/0001193125-26-338523.md) |
| Total assets | $m | [20.3](/filings/0001213900-20-005813.md) | [22.9](/filings/0001213900-21-014712.md) | [689](/filings/0001213900-22-016405.md) | [1,390](/filings/0001213900-23-024297.md) | [1,203](/filings/0001213900-24-024783.md) | [1,064](/filings/0001410578-25-001194.md) | [903](/filings/0001193125-26-134641.md) | not reported | not reported | [638](/filings/0001193125-26-338523.md) | [573](/filings/0001193125-26-211930.md) | [557](/filings/0001193125-26-338523.md) |
| Current liabilities | $m | [3.6](/filings/0001213900-20-005813.md) | [4.4](/filings/0001213900-21-014712.md) | [6.7](/filings/0001213900-22-016405.md) | [32.0](/filings/0001213900-23-024297.md) | [37.0](/filings/0001213900-24-024783.md) | [34.5](/filings/0001410578-25-001194.md) | [30.1](/filings/0001193125-26-134641.md) | not reported | not reported | [52.5](/filings/0001193125-26-338523.md) | [56.1](/filings/0001193125-26-211930.md) | [46.6](/filings/0001193125-26-338523.md) |
| Total liabilities | $m | [4.7](/filings/0001213900-20-005813.md) | [11.3](/filings/0001213900-21-014712.md) | [22.1](/filings/0001213900-22-016405.md) | [45.7](/filings/0001213900-23-024297.md) | [53.2](/filings/0001213900-24-024783.md) | [48.6](/filings/0001410578-25-001194.md) | [41.8](/filings/0001193125-26-134641.md) | not reported | not reported | [86.2](/filings/0001193125-26-338523.md) | [87.8](/filings/0001193125-26-211930.md) | [75.3](/filings/0001193125-26-338523.md) |
| Shareholders' equity | $m | [15.6](/filings/0001213900-22-016405.md) | [11.6](/filings/0001213900-23-024297.md) | [667](/filings/0001213900-22-016405.md) | [1,343](/filings/0001213900-23-024297.md) | [1,153](/filings/0001193125-26-134641.md) | [1,019](/filings/0001193125-26-134641.md) | [860](/filings/0001193125-26-134641.md) | [835](/filings/0001193125-26-338523.md) | [659](/filings/0001193125-26-338523.md) | [552](/filings/0001193125-26-134641.md) | [485](/filings/0001193125-26-338523.md) | [481](/filings/0001193125-26-338523.md) |

- Cash and equivalents: ifrs-full:CashAndCashEquivalents, us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: ifrs-full:CurrentAssets, us-gaap:AssetsCurrent
- Total assets: ifrs-full:Assets, us-gaap:Assets
- Current liabilities: ifrs-full:CurrentLiabilities, us-gaap:LiabilitiesCurrent
- Total liabilities: ifrs-full:Liabilities, us-gaap:Liabilities
- Shareholders' equity: ifrs-full:Equity, ifrs-full:EquityAttributableToOwnersOfParent, us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest, us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | period not labelled (2025-03-31) | period not labelled (2025-06-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(7.5)](/filings/0001193125-26-211930.md) | [(43.1) d](/filings/0001193125-26-338523.md) | [(7.1)](/filings/0001193125-26-211930.md) | [(23.9) d](/filings/0001193125-26-338523.md) |
| Capital expenditure | $m | [0.3](/filings/0001193125-26-211930.md) | [0.2 d](/filings/0001193125-26-338523.md) | [0.2](/filings/0001193125-26-211930.md) | [0.0 d](/filings/0001193125-26-338523.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities, us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | period not labelled (2025-03-31) | period not labelled (2025-06-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | thousands of shares | [216](/filings/0001193125-26-211930.md) | [217](/filings/0001193125-26-338523.md) | [208](/filings/0001193125-26-211930.md) | [209](/filings/0001193125-26-338523.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 210,839,011 at 2026-08-05, from the cover of the [10-Q filed 2026-08-07](/filings/0001193125-26-338523.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:45 ET. No prices; not investment advice.